Glomerulonephritis

This trial tests an experimental oral drug called EVER001 in people with primary membranous nephropathy, a kidney disease where the immune system damages the kidney's filtering units, causing protein to leak into urine. The study aims to see if EVER001 can reduce proteinuria and …

This study followed 591 adults with eosinophilic granulomatosis with polyangiitis (EGPA) across Europe to see how well mepolizumab 300mg every 4 weeks works over the long term in everyday medical practice. Researchers looked at disease control, lung function, and safety by review…

This early-stage trial tests a new daily pill, IPG11406, in 36 adults with lupus nephritis—a kidney complication of lupus. The study checks if the drug is safe and whether it can reduce protein in the urine and improve kidney function. It is too soon to know if it works, but the …

This trial tests whether obinutuzumab, a next-generation antibody, can help people with membranous nephropathy—a kidney disease that causes protein leakage and swelling—who haven't responded well to the standard drug rituximab or who can't take it due to allergic reactions. About…

This study looked at 159 people with granulomatosis with polyangiitis (GPA), a rare disease that causes inflammation of blood vessels. Participants were randomly assigned to either stay on a low 5 mg daily dose of prednisone or slowly stop it over six months. The goal was to see …

This trial tests an experimental drug called HRS-5965 in people with primary IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can reduce protein leakage in the urine, a sign of kidney damage. About 123 adults with confirmed IgA nep…

This study tested whether adding the drug atrasentan to standard care (including SGLT2 inhibitors) can reduce protein in the urine of people with IgA nephropathy, a kidney disease. 54 adults with biopsy-confirmed IgA nephropathy participated. The main goal was to see if atrasenta…

This early-stage study tests a drug called felzartamab in 14 people with active lupus nephritis, a kidney condition caused by lupus. The drug is a lab-made antibody designed to lower harmful antibody buildup in the kidneys. The main goal is to check safety and how the drug works …

This phase 2 trial tests felzartamab (MOR202), an antibody that targets CD38 on plasma cells, in people with membranous nephropathy who did not improve with rituximab or similar therapies. The goal is to reduce protein leakage in urine and achieve remission of nephrotic syndrome.…

This study tested a new drug called BION-1301 in 103 healthy volunteers and adults with IgA nephropathy, a kidney disease. The main goal was to check the drug's safety and how the body processes it. Researchers measured side effects, blood pressure, and kidney function over time.

This study tested a new drug called XH-S003 in 25 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage, after 90 days. Participants had to have a kidney biopsy confirming the disease. T…

This early-stage trial tested a drug called itolizumab (EQ001) in 52 adults with lupus, some of whom also had active kidney inflammation. The main goal was to check safety and find the right dose. Researchers also looked at how the drug behaves in the body and how it affects immu…

This study tested whether a probiotic supplement could change gut bacteria and reduce harmful antibodies that damage kidneys in IgA nephropathy. 18 adults with the disease took probiotics for 3 months. Researchers measured changes in antibody levels and kidney function to see if …

This early-stage study tested a drug called mezagitamab in 17 people with IgA nephropathy, a kidney disease. The main goal was to check for side effects and see how the body processes the drug. Participants received injections under the skin for several weeks and were monitored f…

This study tested whether finerenone, a drug that blocks a hormone involved in kidney damage, can reduce protein in urine and slow kidney function decline. One hundred adults with non-diabetic glomerulonephritis took either finerenone or a placebo for 9 months, on top of their us…

This study tested a new drug called HSK39297 in 87 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug could lower protein levels in urine, a sign of kidney damage, compared to a placebo. Participants took the drug or placebo for up to 24 weeks, and res…

This completed early-stage trial tested an experimental drug called ARO-C3 in 62 healthy volunteers and patients with two types of kidney disease (C3 glomerulopathy and IgA nephropathy). The drug is designed to calm an overactive part of the immune system that can damage the kidn…

This early-stage trial tested a drug called ARO-CFB in 49 healthy volunteers and people with IgA nephropathy, a kidney disease where the immune system damages the kidneys. The main goal was to check safety and how the drug moves through the body. Participants received either one …

This early-phase trial tested the safety of a new drug called VIS649 in 51 healthy volunteers. VIS649 is an antibody that blocks a protein called APRIL, which is thought to play a role in IgA nephropathy, a kidney disease. The study gave single doses of the drug or a placebo and …

This Phase 2 trial tested a drug called felzartamab in 54 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug targets immune cells to reduce protein leakage in urine, a sign of kidney damage. The study compared felzartamab to a placebo to see i…

This study tested a new drug called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers monitored sid…

This phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…

This study tested a new drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine, a sign of kidney damage, and find the best dose. Participants took either the drug or a placebo for a set period, and…

This study followed about 300 people with EGPA (a rare disease causing inflammation in blood vessels) who were treated with Nucala injections for up to 2 years. Researchers monitored side effects, how well the drug controlled symptoms, and how long it took for the disease to flar…

This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during rou…

This early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…

This study looked back at medical records of 56 adults with lupus nephritis to compare two drugs: telitacicept and belimumab. The goal was to see which drug better protects kidney function and causes fewer side effects. Participants had already been on one of the drugs for at lea…

This study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…

This study tested whether the drug rituximab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) achieve remission better than standard treatments. 107 adults with active EGPA were randomly assigned to receive either rituximab or conven…

This phase 3 trial tested iptacopan (LNP023) in 518 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants received either the drug or a placebo, on top of standard care. The goal was to see if iptacopan reduces protein in the urine and slows …

This phase 2 study tested the drug efgartigimod in 73 Chinese patients with active lupus nephritis, a serious kidney complication of lupus. Participants received either the drug or a placebo by IV infusion over 24 weeks. The main goal was to see if the drug could reduce protein i…

This study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…

This study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to …

This study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…

This study tested whether adding sparsentan to a standard SGLT2 inhibitor can better protect kidneys in people with IgA nephropathy, a disease that can lead to kidney failure. 48 adults who were already on stable doses of both a blood pressure drug and an SGLT2 inhibitor took spa…

This study tested whether rituximab (given as an infusion every 6 months) is better than azathioprine (daily pills) at keeping eosinophilic granulomatosis with polyangiitis (EGPA) in remission. 98 adults with newly diagnosed or relapsing EGPA who had already achieved remission to…

This study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either ri…

This study tested whether adding early steroids or SGLT2 inhibitors to standard blood pressure medication can better protect kidney function in people with IgA nephropathy who have severe kidney damage. 62 adults with active disease were randomly assigned to receive either the co…

This study looked at whether giving rituximab for 46 months instead of the usual 18 months can better prevent relapses of ANCA-associated vasculitis, a rare autoimmune disease that causes blood vessel inflammation. 97 patients who were already in remission after initial rituximab…

This study tested a new drug, MIL62, in 94 adults with primary membranous nephropathy, a serious kidney condition. The goal was to see if MIL62 is safe and can help reduce protein in the urine better than the standard drug cyclosporine. Participants received either MIL62 or cyclo…

This study tested a new drug called KZR-616 (zetomipzomib) in 69 people with lupus, some of whom also had kidney inflammation (lupus nephritis). Participants received weekly injections for 13 or 24 weeks. The main goals were to check safety and see if the drug could reduce protei…

This study tested a mobile app called UrApp designed to help families manage childhood nephrotic syndrome, a chronic kidney disease. 58 caregivers of children with the condition were randomly assigned to use the app or receive standard care for one year. The goal was to see if th…

This study tested three doses of a drug called BI 655064 in 121 people with active lupus nephritis, a kidney complication of lupus. The goal was to see if the drug, given as a shot under the skin, could improve kidney function after one year when added to standard treatments. The…

This study tested two different drug combinations for people with active lupus nephritis, a serious kidney condition caused by lupus. It compared tacrolimus plus steroids against mycophenolate mofetil plus steroids. The goal was to see which combination better controlled kidney d…

This study looked at whether people with lupus-related kidney inflammation (lupus nephritis) who have been stable for two years can safely stop taking immunosuppressive drugs like mycophenolate mofetil or azathioprine. One hundred patients were split into two groups: one continue…

This study tested whether adding azathioprine to standard corticosteroid treatment helps people with certain types of vasculitis (blood vessel inflammation) achieve remission and avoid relapses. 114 newly diagnosed patients without poor prognosis factors took part. The goal was t…

This study tested two ways of giving rituximab to people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. All 166 participants were in remission and received rituximab either on a fixed schedule or only when certain blood markers (ANC…

This study looked at 52 adults with EGPA (a rare inflammatory disease) and severe chronic sinusitis with nasal polyps. They received mepolizumab 300 mg every 4 weeks. The goal was to see if the drug reduces polyp size and improves symptoms like nasal congestion and sense of smell…

This study tested whether a low dose (4.5 mg) of naltrexone, a drug already used for alcoholism, can improve physical health and quality of life in people with vasculitis. Sixty participants took either the drug or a placebo daily for six weeks. The goal was to see if the drug le…

This study followed 293 people with autoimmune diseases and healthy volunteers to see how COVID-19 infection or vaccination affects their immune system, inflammation, and blood vessels. Participants were grouped based on their COVID-19 history and had up to 5 visits over 12-18 mo…

This trial tests whether rituximab, a drug used for ANCA-associated vasculitis, leaves patients with a weakened immune system. Researchers give pneumococcal vaccines to patients treated with rituximab, patients with the disease but not on rituximab, and healthy volunteers. They c…

This study looks at whether a protein in the blood, called soluble CD95 ligand, plays a role in ANCA-associated vasculitis, a rare group of diseases that cause inflammation of blood vessels. Researchers will collect blood and urine samples from 48 adults with the condition and tr…

This study looks at how IgA nephropathy, a kidney disease, is actually treated in the United States. By analyzing medical records from thousands of patients, researchers aim to understand which therapies are used, in what order, and for how long. The goal is to see how current tr…

This study explores whether a special type of PET/CT scan, using a radioactive tracer called 18F-FDG, can accurately measure disease activity in people with granulomatosis with polyangiitis (GPA), a rare condition that causes inflammation of blood vessels. Researchers will compar…

This study looks at immune cell patterns in people with three types of nephrotic syndrome—membranous nephropathy, minimal change disease, and focal segmental glomerulosclerosis. Researchers aim to see if certain immune cells can serve as biomarkers to track how well a patient res…

This study looked at immune cells (T and B cells) in the blood of 44 people with a kidney disease called membranous nephropathy. Researchers wanted to see how these cells relate to treatment response and disease relapse. They also measured specific antibodies linked to the diseas…

This study follows 211 people with IgA nephropathy who previously took a 6-9 month course of the steroid methylprednisolone in the TESTING trial. Researchers want to see if the steroid helped prevent end-stage kidney disease (needing dialysis or a transplant) over the long term. …

This study followed 69 people in Taiwan with lupus nephritis who were newly prescribed the drug Myfortic (mycophenolate sodium). Researchers tracked side effects and reasons for stopping the drug over 12 months. The goal was to understand the drug's safety in this specific popula…

This study looked at the IgA antibodies in 80 people — 40 with IgA nephropathy (a kidney disease) and 40 healthy volunteers. Researchers took one blood sample from each person to analyze the IgA repertoire. The goal was to understand why IgA deposits form in the kidneys, which co…

This completed study looked at why people with IgA nephropathy (a kidney disease) often experience memory and attention problems. Researchers used powerful 7-Tesla MRI scanners to examine the brains of 100 patients and 100 healthy volunteers, along with analyzing their gut bacter…

This completed study looked at over 107,000 patients in Germany to understand the long-term side effects of systemic steroids (corticosteroids) used for conditions like asthma, COPD, and arthritis. Researchers compared patients who took steroids with those who did not, tracking r…

This study looked at information from about 70,000 adults receiving hemodialysis around the world to find out how many have IgA nephropathy (a type of kidney disease) and how it affects their health. Researchers compared patients with IgA nephropathy to other dialysis patients to…

This study looked at immune cells from 138 people with Wegener's granulomatosis, a rare disease causing inflammation of blood vessels. Researchers measured levels of a protein called DAP12 in different immune cells to understand how the disease works. No new treatment was tested;…

This completed lab study took blood samples from 20 adults with relapsed membranous nephropathy, a kidney condition. Researchers tested different immune-modulating drugs on the blood cells to see how they affect the balance of Th17 and Treg immune cells. The goal is to find which…

This study looks at a new blood test that measures specific antibodies in people with membranous nephropathy, an autoimmune kidney disease. The test aims to predict which patients are more likely to develop kidney failure. Researchers will follow 52 adults over time to see if the…

This study looks at blood samples from 48 people with membranous nephropathy, a kidney disease. Researchers used a special test to measure immune cells (B cells) that target a protein called PLA2R. The goal is to see how these cells change after treatment with B-cell depleting dr…

This study compares two blood-filtering techniques—plasma exchange and immunoadsorption—in 40 patients with severe kidney failure caused by ANCA vasculitis or Goodpasture disease. The goal is to see which method removes disease-causing antibodies more quickly. Results may help do…

This study looked at whether a specific antibody, called anti-GBM, could be a useful marker for lupus nephritis—a serious kidney complication of lupus. Researchers tested stored blood samples from 100 people with lupus (some with kidney issues, some without) and compared them to …

This study looked at 193 people with lupus nephritis (kidney inflammation caused by lupus) in five Gulf countries. Researchers collected information on their symptoms, treatments, and quality of life, but did not test any new medicine. The goal was to better understand the diseas…

This study followed nearly 6,000 people with kidney disease from around the world. Researchers collected routine test results like kidney function and protein in urine to better understand how the disease progresses. The goal was to gather information, not to test a new treatment…

This study looked at how certain immune cells, called neutrophils, behave in people with granulomatosis with polyangiitis (GPA), a rare blood vessel inflammation disease. Researchers collected blood samples from 93 participants, including patients with GPA and other related condi…